New Insights into the Management of Intrahepatic Cholangiocarcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 2552
Special Issue Editor
Interests: surgical oncology; liver cancers; pancreatic cancers; biliary cancers; liver surgery; pancreatic surgery; biliary surgery; minimally invasive surgery; robotic surgery
Special Issue Information
Dear Colleagues,
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer, showing a steady increase in its incidence and mortality over time in most locations worldwide. It appears above the second-order bile ducts and can also present in a mixed form with hepatocellular carcinoma (HCC).
Only a minority of patients diagnosed with iCCA are amenable of surgical resection (<20%), which represents the only curative option, and are still burdened with dismal survival (15-40% at 5 years) and a high recurrence rate.
The diagnostic and therapeutic management of iCCA is complex, due to significant variations in disease course and outcome in relation to tumor stages and different molecular profiling, mandating a multidisciplinary approach involving histopathology, interventional radiology, oncology, surgical oncology, and radiotherapy professionals.
Recently, several genomic and immunohistochemistry biomarkers have been analyzed, risk models and nomograms have been developed, and surgical and non-surgical treatment options have been explored in an effort to guide clinicians to identify the best strategies and improve the prognosis of both patients with resectable and unresectable disease.
Due to such an intricated scenario, this Special Issue aims to focus on the latest advances in iCCA classification, diagnosis, prognosis, and treatments.
Dr. Gianluca Rompianesi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- intrahepatic cholangiocarcinoma
- liver cancer
- biliary tract neoplasm
- diagnosis
- therapies
- treatment
- outcome